西亚试剂:Yesterday's announcement that London-based Cell Medica had

发布时间：2025-06-28

Yesterday's announcement that London-based Cell Medica had raised a whopping $78 million to fund its work on T-cell therapies for cancer once again shoved fund manager Neil Woodford into the biotech spotlight. Woodford's fund joined the Cell Medica syndicate that's backing its work on immunotherapy, marking his second foray into biotech investing in a matter of days. The move closely followed his decision to take a sizable stake in Bethesda, MD-based Northwest Biotherapeutics ($NWBO), which is developing a controversial brain cancer drug.

A high-profile figure from his days at Invesco, Woodford has become a celebrity of sorts in the biopharma field in the U.K., which is largely clustered around London, Oxford and Cambridge. He mounted a loud campaign in favor of AstraZeneca when the British pharma giant was using a form of corporate jiu-jitsu to fend off a takeover attempt by Pfizer ($PFE). Woodford has also signaled his intention to start a second fund devoted entirely to biotech, which can only expand his already outsized presence in the industry.

In many ways, Woodford represents something that's desperately needed in the U.K. British scientists can hold their own with the best investigators at MIT, Harvard or Stanford. But biotech in the U.K. has been badly starved of cold, hard cash--and nothing eats up cash like advanced drug development. Woodford, who quickly assembled more than $5 billion for his own fund, promises to add $314 million to that with a second biotech fund.

But Woodford is also not a parochial player. Cell Medica and Northwest are both transatlantic biotechs. In Cell Medica's case, it has IP from Baylor in Texas, expertise in the U.K. and manufacturing in Germany. Maryland-based Northwest has been doing much of its research work in Europe, scoring the U.K.'s first designation as a "Promising Innovative Medicine" that can earn fast-track review status. And one of his first biotech investments with the new fund was with Prothena, the Dublin-based Elan spinoff with labs in South San Francisco.

In the U.S., you can often hear jokes about venture groups' reluctance to travel to a bordering state, let alone another continent. As a result, biotech hubs like Boston--where VCs cluster--have achieved a powerful rep as capitols of innovation, attracting Big Pharma R&D like bees to flowers. But what makes Woodford such a potent figure is the example he sets in backing global drug development, where even small companies knit together scientific, administrative and support functions from an international cast of players. Looping Asian players into the game will be the industry's next big step.

Distinct from the British government's episodic forays into supporting R&D, Woodford represents the potential influence of global capital on a more diverse set of biotech hubs, including some long-neglected regions. If he inspires just one or two more groups to do the same, the investor's influence on biotech could be profound.

• 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   
• 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购

 

上一篇：泛生子宣布签署私有化协议
下一篇：西亚试剂:中国种业十大功勋人物傅廷栋：搞农业就要多下田